At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
MORAb-202 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
In Brief
A Phase 2 clinical trial evaluating MORAb-202, Paclitaxel, and 2 other interventions for Neoplasms, Ovarian. Completed, enrolled 106 participants across 50 sites in 9 countries.
Detailed Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Ovarian
CountriesAustralia, Belgium, Chile, Israel, Italy, Japan, South Korea, Spain, United States
CollaboratorsEisai Inc.
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedNov 2022
Enrollment StartFeb 2023
Primary CompletionJun 2024
Study CompletionSep 2025
TodayJul 2026
First PostedNov 14, 2022
Enrollment StartFeb 1, 2023
Primary CompletionJun 17, 2024
Study CompletionSep 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.6 years ago
Interventions
MORAb-202drug
Specified dose on specified days
Paclitaxeldrug
Specified dose on specified days
Pegylated Liposomal Doxorubicin (PLD)drug
Specified dose on specified days
Topotecandrug
Specified dose on specified days